Commentary|Videos|November 26, 2024
Complexities with Managing the Overabundance of Clinical Technology
Author(s)Andy Studna, Senior Editor
In this video interview, Jeff Sidell, PhD, chief technology officer, Advarra, discusses how sites are being burdened by increasingly complex technologies.
Advertisement
In a recent video interview with Applied Clinical Trials, Jeff Sidell, PhD, chief technology officer, Advarra, discussed current challenges in clinical research technology. He highlighted the overabundance of systems and emphasized the need for integration to streamline processes and reduce administrative overhead. Sidell also discussed the potential of AI, particularly predictive analytics, to automate repetitive tasks, enhancing efficiency and quality.
A transcript of Sidell’s conversation with ACT can be found below.
ACT: What are some current trends and challenges you’re seeing right now with technology in clinical research?
Sidell: I think for the most part, it's an overabundance of technology. If you ask somebody who's working in a clinical trial at a site, how many systems they have to touch during the conduct of a clinical trial, it keeps rising over the years. I think it's now up to 20 or so. I mean, 20 separate systems that they've got to go and log into, enter data, or move data from one place to another. Not only are the systems becoming more complicated, the trials themselves are becoming more complicated, so they're going on for longer, the conduct of the trial is much more complex, so you put those two things together, and they're drowning in activities, none of which are actually administering care to a subject. It's all just overhead.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- Q&A: Strategies for Successful Global Clinical Trial Delivery
September 12th 2025
- Vabysmo Shows Long-Term Efficacy and Safety in Wet AMD, PCV Patients
September 12th 2025
- Latest NIMBLE Study Results Highlight Progress in gMG Research
September 12th 2025
- ACT Brief Episode 8: Expert Insights on the Future of Obesity Drug Trials
September 11th 2025
Advertisement
Advertisement